Bicara Therapeutics (BCAX) Q4 2025 earnings summary

Executive summary

• Achieved FDA Breakthrough Therapy Designation for ficerafusp alfa (FICERA) in combination with pembrolizumab for metastatic or unresectable HPV-negative head and neck squamous cell carcinoma, advancing to pivotal Phase III FORTIFY-HN01 trial with substantial enrollment expected by end of 2026 and interim analysis anticipated mid-2027.

• Selected 1500mg weekly dose as optimal and initiated development of less frequent loading and maintenance dosing regimens.

• Presented robust Phase 1b clinical data showing deep, durable responses, improved survival, and consistent efficacy and safety across dosing regimens.

• Completed an oversubscribed public offering, raising $161.8 million to support clinical, commercial, and medical investments for potential U.S. launch.

• Announced plans for key commercial hires and participation in major industry conferences to support launch readiness.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $414.8 million as of December 31, 2025, bolstered by the Q1 2026 public offering.

• Total operating expenses for 2025 increased year-over-year, reaching $125.1 million, driven by higher clinical operations, manufacturing, and personnel costs.

• Net loss for 2025 was $138.0 million, up from $68.0 million in 2024.

• Research and development expenses were $33.0 million for Q4 2025 and $125.1 million for FY 2025.

• General and administrative expenses were $8.1 million for Q4 2025 and $30.5 million for FY 2025.

Outlook and guidance

• Interim analysis for pivotal FORTIFY-HN01 study anticipated mid-2027, with substantial enrollment by end of 2026.

• Long-term follow-up and expansion cohort data to be presented in 2026; commercial build-out and key hires planned.

• Cash position supports regulatory filing, commercial build-out, and further development of ficerafusp alfa, including alternative dosing and indication expansion.

• Data from Phase 1b expansion cohort in metastatic colorectal cancer expected in H2 2026.

• Cash runway guidance into first half of 2029.